Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Cancer Res. 2011 Mar 1;71(5):1858–1870. doi: 10.1158/0008-5472.CAN-10-3604

Figure 5.

Figure 5

A) Impact of CIN+ on disease free survival, overall survival, and those receiving adjuvant chemotherapy in loco-regional CRC. Overall CIN+ appears to confer a worse prognosis compared to diploid.

B) Benefit derived from adjuvant 5-FU in patients with (near) diploid (top) and CIN+ (middle) CRC. Patients with diploid CRC appear to benefit more from chemotherapy compared to patients with CIN+ tumours. Combined analysis of CIN+ and diploid patients shows similar magnitude of benefit as would be expected from literature (bottom) (49).